Medical use of cannabis for dry eye disease

(November 2018)

Background

The clinical value of cannabis in alleviating the symptoms of dry eye disease (DED) is limited at this time due to a lack of clinical evidence.

The Canadian Ophthalmological Society does not support the medical use of cannabis for the treatment of DED or its associated pain symptoms, due to its undesirable side-effects, including dry eye symptoms if smoked, and the absence of scientific evidence showing any beneficial effect at this time.

Other evidence-based, less harmful treatment modalities are available for DED and its associated symptoms.

Access Details

Read the full position statement and recommendations from the Canadian Ophthalmological Society (COS).

Related Resources

Accreditation Toolkit

Access the resources to assist you with designing and delivering...

More Info

Co-developed CPD Activity Resources

Access these resources to assist you with designing and delivering...

More Info

Article from the AAO : Ocular Signs of COVID-19 Suggested by Internet Search Term Patterns Worldwide

August 24, 2020 Ocular Signs of COVID-19 Suggested by Internet...

More Info
Can Ophthal Society's Twitter via Twitter Web Client